<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688203</url>
  </required_header>
  <id_info>
    <org_study_id>6601</org_study_id>
    <nct_id>NCT04688203</nct_id>
  </id_info>
  <brief_title>Effects Magnesium Sulfate and Labetalol Infusion on Peripheral Perfusion and Pain in Nasal Surgeries</brief_title>
  <official_title>Effects of Magnesium Sulfate and Labetalol Infusion Used for Induced Hypotension on Peripheral Perfusion and Postoperative Pain in Nasal Surgeries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of main risk of controlled hypotension during nasal surgeries is impaired perfusion.&#xD;
      Peripheral perfusion of non-vital organs usually impaired earlier than vital organs. So,&#xD;
      evaluation of perfusion of non-vital organ is considered to be adequate measure of patient&#xD;
      safety during surgery.&#xD;
&#xD;
      Many hypotensive agents such as dexmedetomidine, B blockers, magnesium sulfate and&#xD;
      nitroglycerine had been used but we are in need to investigate its effects on peripheral&#xD;
      perfusion.&#xD;
&#xD;
      Postoperative pain related to nasal surgeries due to surgical trauma itself which induces the&#xD;
      release of inflammatory mediators from neuronal and immune cells resulting in peripheral and&#xD;
      central sensitization significantly affects recovery of patients. Magnesium sulfate and&#xD;
      labetalol have analgesic actions besides their hypotensive effects but with different&#xD;
      mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare between the effects of magnesium sulfate and labetalol infusion during induced&#xD;
      hypotension on peripheral perfusion and postoperative pain in nasal surgeries&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      To measure peripheral perfusion index (PPI) as an indicator for peripheral perfusion To&#xD;
      calculate the total postoperative rescue analgesic requirements.&#xD;
&#xD;
      Double -blind randomized comparative Clinical Study. All Patients will be randomly allocated&#xD;
      into two equal groups (group M and Group L).&#xD;
&#xD;
      Using computer generated randomization table, each group will be 25 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral perfusion index</measure>
    <time_frame>Changes from baseline Peripheral perfusion index at 2 hours.</time_frame>
    <description>Peripheral perfusion index by pulse oximertry will be measured at basal, 3minutes after induction, every 10 minutes till end of surgery. It will be calculated by dividing the pulsatile signal to nonpulsatile. The normal range is (0.02% -20%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>basal then at 3 minutes after intubation, and after skin incision then every 10 minutes till the end of surgery</time_frame>
    <description>Mean arterial blood pressure will be recorded at basal, 3 minutes after intubation, and after skin incision then every 10 min till the end of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>basal then at 3 minutes after intubation, and after skin incision then every 10 minutes till the end of surgery</time_frame>
    <description>Heart rate will be recorded at basal, 3 minutes after intubation, and after skin incision then every 10 min till the end of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative Pain intensity</measure>
    <time_frame>at 30 minutes, 1 hour, 2hours, 4hours, 6hours, 12hours, and 24hours postoperative.</time_frame>
    <description>Postoperative Pain will be assessed using Numerical rating Scale (NRS) . A commonly used scale is a 10-cm line labeled with &quot;worst pain imaginable&quot; on the right border and &quot;no pain&quot; on the left border. The patient will be instructed to make a mark along the line to represent the intensity of pain currently being experienced. NRS score 4 or more =pain. Paracetamol 1gm IV will be given every 6 hours as a protocol for pain management will be started at the end of surgery, and IV pethidine 1mg/kg (rescue analgesic) will be given if NRS &gt;4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first call for pethidine (rescue analgesic)</measure>
    <time_frame>up to 24hour postoperative</time_frame>
    <description>Time from the stoppage of infusion solution to first call for pethidine (rescue analgesic) will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total pethidine requirements</measure>
    <time_frame>up to 24hour postoperative</time_frame>
    <description>Total pethidine requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate level</measure>
    <time_frame>basal and at one hour after extubation</time_frame>
    <description>Serum lactate will be recorded basal and at one hour after extubation. The normal serum lactate ranges from 4.5 to 19.8 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Perfusion</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Magnesium sulfate infudsion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labetalol infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate Injection</intervention_name>
    <description>will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.</description>
    <arm_group_label>Magnesium sulfate infudsion</arm_group_label>
    <other_name>magnesium sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol Injectable Solution</intervention_name>
    <description>will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.</description>
    <arm_group_label>Labetalol infusion</arm_group_label>
    <other_name>labetalol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent from the patient.&#xD;
&#xD;
          -  Age: 21-45 years old.&#xD;
&#xD;
          -  Sex: both sex (males or females).&#xD;
&#xD;
          -  Physical status: ASA 1&amp; II.&#xD;
&#xD;
          -  BMI = (20-30 kg/m2).&#xD;
&#xD;
          -  Type of operations: elective nasal surgeries such as septoplasty, endoscopic sinus&#xD;
             surgery and polypectomy.&#xD;
&#xD;
          -  Duration of surgery â‰¤ two hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Altered mental state&#xD;
&#xD;
          -  Patients on beta blocker or with known history of allergy to study drugs.&#xD;
&#xD;
          -  Advanced hepatic, renal, cardiovascular or respiratory diseases.&#xD;
&#xD;
          -  Diabetic patients.&#xD;
&#xD;
          -  Patients receiving anticoagulants or on pain killers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alshaimaa Kamel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Human medicine, Zagazig university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alshaimaa Kamel, M.D</last_name>
    <phone>01005593169</phone>
    <phone_ext>002</phone_ext>
    <email>AlshaimaaKamel80@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina Salem, M.D</last_name>
    <phone>01099333513</phone>
    <phone_ext>002</phone_ext>
    <email>dinamaghrapy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alshaimaa Abdel Fattah Kamel</name>
      <address>
        <city>Zagazig</city>
        <zip>002055</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alshaimaa Kamel, M.D</last_name>
      <phone>01005593169</phone>
      <phone_ext>002</phone_ext>
      <email>AlshaimaaKamel80@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dina Salem, M.D</last_name>
      <email>dinamaghraby@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alshaimaa Kamel, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Alshaimaa Abdel Fattah Kamel</investigator_full_name>
    <investigator_title>lecturer of Anesthesia ,and surgical intensive care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

